Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   HEPATITIS MONTHLY   DECEMBER 2013 , Volume 13 , Number 12; Page(s) 1 To 8.
 
Paper: 

EFFICACY OF ALFACALCIDOL ON PEG-IFN/ RIBAVIRIN COMBINATION THERAPY FOR ELDERLY PATIENTS WITH CHRONIC HEPATITIS C: A PILOT STUDY

 
 
Author(s):  ATSUKAWA MASANORI*, TSUBOTA AKIHITO, SHIMADA NORITOMO, ITOKAWA NORIO, NAKAGAWA AI, HASHIMOTO SATOMI, FUKUDA TAKESHI, MATSUSHITA YOKO, KIDOKORO HIDEKO, NARAHARA YOSHIYUKI, NAKATSUKA KATSUHISA, IWAKIRI KATSUHIKO, KAWAMOTO CHIAKI, SAKAMOTO CHOITSU
 
* DIVISION OF GASTROENTEROLOGY, DEPARTMENT OF INTERNAL MEDICINE, NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL, 1715, KAMAKARI, INZAI, 270-1694, CHIBA, JAPAN
 
Abstract: 

Background: Serum vitamin D concentration is reported to show a decrease in older age. Patients with chronic hepatitis C (CHC) in Japan are older on average than those in Western countries. Moreover, the outcome of pegylated-interferon (PEG-IFN)/ ribavirin therapy combined with vitamin D in elderly patients is unclear.
Objectives: This pilot study explored the efficacy and safety of alfacalcidol as vitamin D source in PEG-IFN/ ribavirin combination therapy for elderly CHC patients infected with hepatitis C virus genotype 1b.
Patients and Methods: Consecutive twenty CHC patients aged
³ 65 years were enrolled in this pilot study. Fifteen patients met the inclusion criteria and received PEG-IFN/ ribavirin therapy combined with alfacalcidol. Four-week lead-in of oral alfacalcidol was conducted, and it was subsequently and concurrently administered in PEG-IFN/ ribavirin combination therapy (vitamin D group). Age, gender, and IL28B genotype-matched patients, who received PEG-IFN/ ribavirin alone, were saved as control group (n = 15) to compare the treatment outcome with the vitamin D group.
Results: Subjects consisted of 14 males and 16 females, with a median age of 70 years (65-78). The serum 25 (OH) D3 concentration in females (20 ng/ml, 11-37) was significantly lower than males (27 ng/mL, 13-49) (P = 0.004). Sustained virological response (SVR) rates were 33.3% (5.15) in the control group and 80.0% (12.15) in the vitamin D group, respectively (P = 0.025). While no significant difference was shown in the SVR rate between the two groups among males (P = 0.592), in females the SVR rate was significantly higher in the vitamin D group (87.5%, 7.8) than the control group (25.0%, 2.8) (P = 0.041). The relapse rates in the groups with and without alfacalcidol were 7.7% (1.13) and 61.5% (8.13), respectively (P = 0.011). Interestingly, in females, the relapse in the control group was shown in 5 of 7 (71.4%), whereas in the vitamin D group the relapse rate was decreased (1.8, 12.5%) (P = 0.041). No specific adverse events were observed in the vitamin D group.
Conclusions: PEG-IFN/ ribavirin combined with alfacalcidol may be effective and safe in elderly CHC patients. In particular, concomitant administration of alfacalcidol may lead to a reduced relapse rate, and consequently improving the SVR rate in elderly females.

 
Keyword(s): 1-HYDROXYCHOLECALCIFEROL, VITAMIN D, RIBAVIRIN, AGED, HEPATITIS C, CHRONIC
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

ATSUKAWA, M., & TSUBOTA, A., & SHIMADA, N., & ITOKAWA, N., & NAKAGAWA, A., & HASHIMOTO, S., & FUKUDA, T., & MATSUSHITA, Y., & KIDOKORO, H., & NARAHARA, Y., & NAKATSUKA, K., & IWAKIRI, K., & KAWAMOTO, C., & SAKAMOTO, C. (2013). EFFICACY OF ALFACALCIDOL ON PEG-IFN/ RIBAVIRIN COMBINATION THERAPY FOR ELDERLY PATIENTS WITH CHRONIC HEPATITIS C: A PILOT STUDY. HEPATITIS MONTHLY, 13(12), 1-8. https://www.sid.ir/en/journal/ViewPaper.aspx?id=412439



Vancouver: Copy

ATSUKAWA MASANORI, TSUBOTA AKIHITO, SHIMADA NORITOMO, ITOKAWA NORIO, NAKAGAWA AI, HASHIMOTO SATOMI, FUKUDA TAKESHI, MATSUSHITA YOKO, KIDOKORO HIDEKO, NARAHARA YOSHIYUKI, NAKATSUKA KATSUHISA, IWAKIRI KATSUHIKO, KAWAMOTO CHIAKI, SAKAMOTO CHOITSU. EFFICACY OF ALFACALCIDOL ON PEG-IFN/ RIBAVIRIN COMBINATION THERAPY FOR ELDERLY PATIENTS WITH CHRONIC HEPATITIS C: A PILOT STUDY. HEPATITIS MONTHLY. 2013 [cited 2021October27];13(12):1-8. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=412439



IEEE: Copy

ATSUKAWA, M., TSUBOTA, A., SHIMADA, N., ITOKAWA, N., NAKAGAWA, A., HASHIMOTO, S., FUKUDA, T., MATSUSHITA, Y., KIDOKORO, H., NARAHARA, Y., NAKATSUKA, K., IWAKIRI, K., KAWAMOTO, C., SAKAMOTO, C., 2013. EFFICACY OF ALFACALCIDOL ON PEG-IFN/ RIBAVIRIN COMBINATION THERAPY FOR ELDERLY PATIENTS WITH CHRONIC HEPATITIS C: A PILOT STUDY. HEPATITIS MONTHLY, [online] 13(12), pp.1-8. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=412439.



 
  pdf-File
Yearly Visit 41
 
 
Latest on Blog
Enter SID Blog